profit from every $100 of sales.
$0$100
Viatris
$20.82+0.73% today
+90.8% in 1 year
1-year low $10.191-year high $21.06
Trading close to its highest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What Viatris sold, what it kept, and what it did with the cash.
Sales went from $16.3 billion in 2022 to $14.3 billion in 2025, with -$3.51 billion of profit last year.
SalesProfit
Viatris handed back 57% of the cash it generated last year.
Buybacks $501M$561M
Free cash flow 2025$1.9B
Bought back its own shares$501M
Paid as dividends$561M
Cash vs. debt$1.3B vs. $14.7B
Viatris vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| Viatris | No profit yet | ||
 Merck KGaA | 24.9× · Fair price | ||
 Takeda Pharmaceutical | 102.5× · Very expensive | ||
 Galderma Group | 86.9× · Very expensive | ||
 Teva Pharmaceutical Industries | 36.8× · Expensive |
AI analysis
An AI analyst reads Viatris's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 11,946 | 17,886 | 16,263 | 15,427 | 14,739 | 14,300 | |
| 3,797 | 5,576 | 6,497 | 6,439 | 5,624 | 5,014 | |
| – | – | 1,656 | 1,563 | 710 | 254 | |
| 1,993 | 4,478 | 6,433 | 3,517 | 2,820 | -395 | |
| -670 | -1,269 | 2,079 | 55 | -634 | -3,515 | |
| -1.11 | -1.05 | 1.71 | 0.05 | -0.53 | -3.00 | |
| 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% | |
| – | – | 10.2% | 10.1% | 4.8% | 1.8% | |
| -5.6% | -7.1% | 12.8% | 0.4% | -4.3% | -24.6% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 61,553 | 54,843 | 50,022 | 47,686 | 41,501 | 37,193 |
| Cash | 844 | 701 | 1,260 | 992 | 735 | 1,322 |
| Total debt | 25,839 | 23,088 | 19,528 | 18,371 | 14,306 | 14,698 |
| Total liabilities | 38,599 | 34,350 | 28,950 | 27,218 | 22,865 | 22,482 |
| 22,954 | 20,493 | 21,072 | 20,467 | 18,636 | 14,711 | |
| 601 | 1,209 | 1,217 | 1,207 | 1,193 | 1,171 | |
| -0.4% | -0.1% | 6.6% | 1.6% | -0.2% | -8.6% | |
| -2.9% | -6.2% | 9.9% | 0.3% | -3.4% | -23.9% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 1,232 | 3,017 | 2,999 | 2,900 | 2,303 | 2,316 | |
| – | – | 489 | 575 | 359 | 465 | |
| – | – | 2,510 | 2,325 | 1,944 | 1,851 | |
| Dividends paid | – | – | 582 | 576 | 575 | 561 |
| 0 | 0 | 0 | 250 | 250 | 501 | |
| 79 | 111 | 116 | 181 | 146 | 178 |
Valuation
- –
- 8.5×
- –
- 1.3×
- 1.7×
- 12.9×
- –
- 7.8%
- -14.7%
- 2.9%
Profitability
- 35.1%
- 1.8%
- -24.6%
- 13.0%
- 0.2%
- -2.3%
- -2.0%
- -0.8%
- 0.5%
- 6.8%
Growth
- +3.7%
- –
- −2.0%
- –
- −0.8%
Financial health
- –
- 0.98
- 38.9%
- 0.3×
- 1.60
- 1.03
- 0.40
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 30%of 964
Bottom 25%of 898
Bottom 24%of 911
Top 12%of 991
What analysts expect
- Average price target
- $15.25
- Range
- $12.00 – $18.00
- 1 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | 0.59 | 0.52 | +13.5% |
| Feb 26, 2026 | 0.57 | 0.53 | +7.1% |
| Nov 6, 2025 | 0.67 | 0.62 | +7.9% |
| Aug 7, 2025 | 0.62 | 0.56 | +11.5% |
| May 8, 2025 | 0.50 | 0.49 | +1.6% |
| Feb 27, 2025 | 0.54 | 0.61 | −11.5% |
| Nov 7, 2024 | 0.75 | 0.68 | +10.8% |
| Aug 8, 2024 | 0.69 | 0.68 | +1.8% |
2.9%of the share price, paid each year
On $1,000 invested$29a year at today's yield, before tax
–per share
Raised–not every year
Paid per share, each year
$0.33 in 2021 → $0.48 in 2025
How safe it looks
-188.0% of its profit
Room to growStretchedMore than it earns: 30.3%
News
Ingram Micro set to join S&P SmallCap 600 following Viatris-Pacira dealSeeking Alpha · Nov 12, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
0/7Passes 0 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
24No pass
Benjamin Graham
45No pass
Philip Fisher
25No pass
Peter Lynch
26No pass
Joel Greenblatt
0No pass
Charlie Munger
19No pass
Terry Smith
18No pass
Questions about Viatris
Is Viatris a good stock to buy?
A business with weak numbers that is not profitable yet. 0 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the Viatris AI analysis
What does Viatris do?
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It is in Drug Manufacturers - Specialty & Generic, based in Canonsburg, PA, United States, with 30,000 employees.
Does Viatris pay a dividend?
Yes. At today's price the dividend is 2.9% a year. In 2025 it paid out $561 million in dividends.
Is Viatris stock halal?
No. Viatris does not pass our halal screen: its debt is 62% of its market value, at or above the 33% limit. How we check
How has Viatris stock done over the past year?
Up 90.8% over the past twelve months, to $20.82. It traded between $10.19 and $21.06, close to its high.
Who are Viatris's competitors?
The largest listed companies in the same industry are Merck KGaA, Takeda Pharmaceutical, Galderma Group and Teva Pharmaceutical Industries. The peers table on this page compares their profit, growth and price with Viatris's.
Prices: daily closes to Nov 13, 2026. Fundamentals: company reports via invest-like data.